Cargando…
Pharmacogenomic Analysis Reveals CCNA2 as a Predictive Biomarker of Sensitivity to Polo-Like Kinase I Inhibitor in Gastric Cancer
Despite recent innovations and advances in early diagnosis, the prognosis of advanced gastric cancer remains poor due to a limited number of available therapeutics. Here, we employed pharmacogenomic analysis of 37 gastric cancer cell lines and 1345 small-molecule pharmacological compounds to investi...
Autores principales: | Lee, Yunji, Lee, Chae Eun, Oh, Sejin, Kim, Hakhyun, Lee, Jooyoung, Kim, Sang Bum, Kim, Hyun Seok |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352331/ https://www.ncbi.nlm.nih.gov/pubmed/32486290 http://dx.doi.org/10.3390/cancers12061418 |
Ejemplares similares
-
Selective cytotoxicity of a novel mitochondrial complex I inhibitor, YK-135, against EMT-subtype gastric cancer cell lines due to impaired glycolytic capacity
por: Sung, Yeojin, et al.
Publicado: (2022) -
Putting a bit into the polo-box domain of polo-like kinase 1
por: Park, Jung-Eun, et al.
Publicado: (2015) -
Polo-like kinase 4 as a potential predictive biomarker of chemoradioresistance in locally advanced rectal cancer
por: Oh, Hyunseung, et al.
Publicado: (2022) -
Comprehensive pharmacogenomic characterization of gastric cancer
por: Sa, Jason K., et al.
Publicado: (2020) -
WNK3 inhibition elicits antitumor immunity by suppressing PD-L1 expression on tumor cells and activating T-cell function
por: Yoon, Hyun Ju, et al.
Publicado: (2022)